Hot flashes and Night sweet. Flushing
Conditions
Interventions
Intervention 1: Intervention group: Patients in one group will receive Pregabalin 75 mg (Sobhan Darou Company, Rasht, Iran) once a day at bedtime during the first week, followed by 75 mg twice a day f
Sponsors
Birjand University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
45 Years to 57 Years
Inclusion criteria
Inclusion criteria: Women aged 45 to 57 years Have not had menstrual bleeding in the past 12 months Have experienced hot flashes more than twice a day in the past 4 months Serum FSH level over 40 mIU/mL
Exclusion criteria
Exclusion criteria: Women who use multivitamins or blood thinners such as warfarin or other antidepressant medications, or who have undergone chemotherapy Women with depression, psychosis, thyroid disorders, hemophilia, autoimmune disorders, diabetes, hypertension, or rheumatic heart disease Patients who have received androgens, progestogens, or estrogens
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The frequency of hot flashes. Timepoint: Before and after receiving any of the two treatments for 6 weeks. Method of measurement: Filling out the items 19 of the Green Climacteric Scale questionnaire.;The frequency of night sweats. Timepoint: Before and after receiving any of the two treatments for 6 weeks. Method of measurement: Filling out the items 20 of the Green Climacteric Scale questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactNegin Adel
Birjand University of Medical Sciences
Outcome results
None listed